News & Updates

Antiseizure effect of cannabidiol seen within 2 weeks of treatment
Antiseizure effect of cannabidiol seen within 2 weeks of treatment
28 Mar 2022

In the treatment of patients with drug-resistant epilepsy associated with tuberous sclerosis complex, the antiseizure effect of cannabidiol occurs within 6–10 days, according to the results of a phase III trial. Adverse events also emerge during the first 2 weeks of the titration period, and majority of these are resolved during the 16-week treatment period.

Antiseizure effect of cannabidiol seen within 2 weeks of treatment
28 Mar 2022
Language, math scores poorer in adolescents with childhood-onset chronic rheumatic disease
Language, math scores poorer in adolescents with childhood-onset chronic rheumatic disease
27 Mar 2022

Patients with childhood-onset chronic rheumatic disease (CRD) do not perform as well as their peers on grade 12 standardized testing, independent of sociodemographic and mental health comorbidities, reports a population-based retrospective cohort study.

Language, math scores poorer in adolescents with childhood-onset chronic rheumatic disease
27 Mar 2022
Body roundness index trajectories tied to CVD risk
Body roundness index trajectories tied to CVD risk
27 Mar 2022
IV steroids may do more harm than good in older-onset ulcerative colitis
IV steroids may do more harm than good in older-onset ulcerative colitis
26 Mar 2022

In patients with older-onset ulcerative colitis (UC), treatment with intravenous (IV) steroids appears to be less effective and is associated with higher risks of surgery and adverse events relative to patients with younger-onset disease, a study has found.

IV steroids may do more harm than good in older-onset ulcerative colitis
26 Mar 2022
Moderate intake of dietary isoflavone lowers lung cancer risk in nonsmoking women
Moderate intake of dietary isoflavone lowers lung cancer risk in nonsmoking women
26 Mar 2022